Author + information
- Haruki Sekiguchi,
- Eri Yamamoto,
- Takuro Abe,
- Akiko Sakai,
- Kayoko Sato and
- Nobuhisa Hagiwara
The effectiveness of proprotein convertase subtilisin/kexin type 9(PCSK-9) inhibitors in patients with ischemic heart disease was revealed by FOURIER trials. For secondary prevention, low-density lipoprotein cholesterol(LDL-C) levels should be controlled below 70mg/dL. However, for the patients with heterozygous familial hypercholesterolemia(hFH), it is difficult to reach the target levels of LDL-C with conventional hypolipidemic drugs. We examined the effects of PCSK-9 inhibitors treated with high-risk FH patients.
From 2016, we administered PCSK-9 inhibitors to the patients with hFH. We analyzed the clinical course for first and second prevention, clinical characteristics, biochemical data, physiological examination, and gene mutation in the consecutive 16 high-risk hFH patients(8 male and 8 female) for 24W.
The age of hFH patients was 59.4±13.2 years and BMI was 26.9±4.1 kg/m2. We found 6 of LDLR and 3 of PCSK-9 gene mutations, and 30% of those had double heterozygous mutations. The T-cho, LDL-C, ApoB, LP(a), and oxidized LDL-C were improved significantly after PCSK-9 inhibitor treatments for 4W. In many cases, the maximum carotid artery intima-media thickness(IMT) and achilles tendon xanthoma(ATX), and coronary artery plaques were decreased dramatically after 24W.
The plaque formation in high-risk FH patients was improved following strong lipids-lowering effects by PCSK-9 inhibitor, it could be prevented the future cardiovascular events.
Poster Hall, Hall A/B
Sunday, March 11, 2018, 3:45 p.m.-4:30 p.m.
Session Title: Predictors, Treatments and Outcomes in Peripheral Artery Disease
Abstract Category: 40. Vascular Medicine: Non Coronary Arterial Disease
Presentation Number: 1257-386
- 2018 American College of Cardiology Foundation